Article (Scientific journals)
A review of gliptins for 2014.
Scheen, André
2015In Expert Opinion on Pharmacotherapy, 16 (1), p. 43-62
Peer Reviewed verified by ORBi
 

Files


Full Text
a review for gliptins 2014.pdf
Publisher postprint (369.46 kB)
Request a copy

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
cardiovascular outcome; dipeptidyl peptidase-4 inhibitor; elderly; gliptin; renal insufficiency; therapy; type 2 diabetes mellitus
Abstract :
[en] Introduction: Dipeptidyl peptidase-4 (DPP-4) inhibitors (gliptins) occupy an increasing place in the armamentarium of drugs used for the management of hyperglycaemia and offer new opportunities for a personalized medicine in patients with Type 2 diabetes. Areas covered: An updated review providing an analysis of available recent data with commercialized DPP-4 inhibitors, with a special focus on: differences between the various molecules, novelties regarding their mechanism of action, clinical efficacy in mono- and various combined therapies, comparison with other new therapies, efficacy-safety profile in at risk patients, concern about pancreatic safety, perspectives in cardiovascular prevention and, finally, a selection of remaining unanswered important questions for the clinician. Expert opinion: DPP-4 inhibitors offer various advantages when compared to other glucose-lowering agents. Despite they have been commercialized since a few years only, available data obtained in randomised controlled trials are of better quality compared to those available with ancient classical glucose-lowering agents, especially in more fragile populations such as elderly people, individuals with renal impairment or at high cardiovascular risk and patients at higher risk of hypoglycaemia. However, there remain uncertainties and controversies that should be resolved by further ongoing large prospective controlled trials and increasing clinical experience combined with a careful post-marketing surveillance.
Disciplines :
Pharmacy, pharmacology & toxicology
Endocrinology, metabolism & nutrition
Author, co-author :
Scheen, André  ;  Université de Liège - ULiège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques
Language :
English
Title :
A review of gliptins for 2014.
Publication date :
January 2015
Journal title :
Expert Opinion on Pharmacotherapy
ISSN :
1465-6566
eISSN :
1744-7666
Publisher :
Taylor & Francis, United Kingdom
Volume :
16
Issue :
1
Pages :
43-62
Peer reviewed :
Peer Reviewed verified by ORBi
Available on ORBi :
since 18 December 2014

Statistics


Number of views
109 (2 by ULiège)
Number of downloads
1 (0 by ULiège)

Scopus citations®
 
98
Scopus citations®
without self-citations
63
OpenCitations
 
78

Bibliography


Similar publications



Contact ORBi